Hepatocellular Carcinoma Recurrence and Anesthesia
Completed
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT02643173
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
The investigators will verify the prognosis of hepatocellular carcinoma (HCC) according to the main anesthetic agents used for the general anesthesia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 259
Inclusion Criteria
- Patients undergoing surgery due to the HCC.
Exclusion Criteria
- Patients undergoing re-operation due to the HCC.
- Patients presenting distant metastasis.
- Patients undergoing liver transplantation surgery.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence of HCC Postoperative 2 year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link anesthetic agents to hepatocellular carcinoma recurrence rates post-surgery?
How do volatile anesthetics compare to intravenous agents in preventing HCC recurrence after resection?
Are specific biomarkers associated with HCC recurrence risk influenced by anesthesia type in observational studies?
What adverse events are reported in HCC patients undergoing general anesthesia with sevoflurane or propofol?
How does this trial's anesthesia findings relate to other HCC recurrence prevention strategies like sorafenib or immune checkpoint inhibitors?
Trial Locations
- Locations (1)
Seoul National University Bundang Hospital
🇰🇷Seongnam, Gyeonggi, Korea, Republic of
Seoul National University Bundang Hospital🇰🇷Seongnam, Gyeonggi, Korea, Republic of